Skip to content

US · IMTX · BIOTECHNOLOGY

Immatics N.V. (IMTX) intrinsic value and stock valuation

$5.77as of 2026-11-21 · Mkt cap 1.29B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Immatics N.V. DCF and intrinsic value

InvestorsCraft values IMTX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from IMTX’s statements →

Immatics N.V. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Tübingen, BW 72076 immatics.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$48.3M+9.1% 5y CAGRd
20182025
Net income
-$-196.45M
20182025
Free cash flow
-$-175.95M
20182025
Total equity
$483.9M+35.9% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$48.3M$155.8M$54M$172.8M$34.8M
Operating income-$-182.02M-$-38.62M-$-101.72M$30M-$-86.29M
Net income-$-196.45M$15.2M-$-96.99M$37.5M-$-95.06M
EPSd-$-1.61M$142.5K-$-1.2M$545K-$-1.51M
Operating cash flow-$-169.66M-$-158.03M$18.2M$100.1M-$-81.78M
Capital expenditure-$-6.3M-$-16.48M-$-30.96M-$-6.21M-$-5.66M
Free cash flow-$-175.95M-$-174.51M-$-12.73M$93.9M-$-87.44M
Total assets$562.1M$696.2M$510M$407.8M$174.7M
Total debt$15.6M$16.2M$15.4M$14.6M$9.85M
Net debt-$-330.14M-$-220.54M-$-203.07M-$-133.96M-$-123.14M
Total equity$483.9M$574.8M$225.1M$213.2M$24.1M
Cash and short-term investments$469.1M$604.5M$425.9M$362.2M$145.1M
Income statement
20252024202320222021
Revenue$48.3M$155.8M$54M$172.8M$34.8M
Cost of revenue$0.00$0.00$118.7M$106.8M$87.6M
Gross profit$48.3M$155.8M-$-64.67M$66.1M-$-52.81M
Research and development expenses$183.8M$148.1M$118.7M$106.8M$87.6M
Selling, general and administrative expenses$51.2M$46.5M$38.2M$36.1M$33.8M
Other expenses-$-4.73M-$-80K-$-1.14M-$-30K-$-330K
Operating expenses$230.3M$194.5M$155.7M$142.9M$121.1M
Cost and expenses$230.3M$194.5M$155.7M$142.9M$121.1M
Interest income$17.2M$25M$13.9M$2.48M$130K
Interest expense$950K$890K$830K$1.04M$570K
Depreciation and amortization$12.4M$12.2M$7.23M$6.84M$5.47M
Ebitda-$-185.09M$34.5M-$-88.93M$50M-$-87.3M
Operating income-$-182.02M-$-38.62M-$-101.72M$30M-$-86.29M
Total other income/expenses, net-$-16.42M$60M$4.73M$12.1M-$-7.04M
Income before tax-$-198.44M$21.4M-$-96.99M$42M-$-93.33M
Income tax expense-$-1.99M$6.13M$0.00$4.55M$0.00
Net income-$-196.45M$15.2M-$-96.99M$37.5M-$-95.06M
Weighted average shares outstanding$122.4M$108.7M$80.6M$67.2M$62.9M
Weighted average diluted shares outstanding$122.4M$106.8M$80.6M$68.8M$62.9M
Balance sheet
20252024202320222021
Cash and short-term investments$469.1M$604.5M$425.9M$362.2M$145.1M
Net receivables$6.88M$6.75M$5.74M$1.11M$2.36M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$503.8M$629.6M$449.4M$377.2M$152.2M
Property, plant and equipment, net$54.9M$63.7M$57.1M$26.5M$20.5M
Goodwill and intangible assets$1.58M$1.63M$1.52M$1.63M$1.31M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$58.3M$66.6M$60.6M$30.7M$22.4M
Total assets$562.1M$696.2M$510M$407.8M$174.7M
Accounts payable$340K$10.1M$7.67M$4.03M$3.01M
Short-term debt$2.76M$2.85M$2.6M$2.16M$2.71M
Deferred revenue$15.8M$35.9M$100.4M$65M$50.4M
Total current liabilities$43M$68M$156.6M$106.5M$95.2M
Long-term debt$12.9M$13.4M$12.8M$12.4M$7.14M
Deferred revenue, non-current$18.5M$34.2M$115.5M$75.8M$48.2M
Total non-current liabilities$35.2M$53.3M$128.3M$88.2M$55.4M
Capital lease obligations$15.6M$16.2M$15.4M$14.6M$9.85M
Total liabilities$78.2M$121.3M$284.9M$194.7M$150.6M
Common stock$1.34M$1.22M$850K$770K$630K
Retained earnings-$-785.65M-$-589.54M-$-597.29M-$-500.3M-$-537.81M
Accumulated other comprehensive income (loss)-$-8.59M$1.03M-$-1.64M-$-1.48M-$-3.94M
Total equity$483.9M$574.8M$225.1M$213.2M$24.1M
Total investments$123.4M$367.7M$207.4M$213.7M$12.1M
Total debt$15.6M$16.2M$15.4M$14.6M$9.85M
Net debt-$-330.14M-$-220.54M-$-203.07M-$-133.96M-$-123.14M
Cash flow statement
20252024202320222021
Net income-$-188.69M$15.2M-$-94.65M$37.5M-$-93.33M
Depreciation and amortization$11.9M$12.2M$7.23M$6.97M$5.26M
Stock-based compensation$0.00$17.6M$20.7M$22.6M$26.4M
Change in working capital-$-42.23M-$-163.88M$81.6M$37.3M-$-31.7M
Accounts receivable-$-230K-$-1.76M-$-2.98M-$-430K$570K
Inventory$0.00$0.00-$-84.24M$0.00$0.00
Accounts payable-$-36.13M$0.00$84.2M$45.6M-$-31.78M
Net cash provided by operating activities-$-169.66M-$-158.03M$18.2M$100.1M-$-81.78M
Investments in property, plant and equipment-$-6.54M-$-16.27M-$-30.8M-$-6.21M-$-5.66M
Acquisitions, net$0.00$0.00$0.00-$-199.91M$550K
Net cash used for investing activities$196.7M-$-152.39M-$-31.39M-$-209.79M$7.49M
Common stock issued$96.4M$343M$90.4M$134.5M$90K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$93.5M$319.7M$84.5M$123.7M-$-2.61M
Net change in cash$137.1M$18.3M$70M$15.5M-$-74.54M
Cash at end of period$345.8M$236.8M$218.5M$148.5M$133M
Operating cash flow-$-169.66M-$-158.03M$18.2M$100.1M-$-81.78M
Capital expenditure-$-6.3M-$-16.48M-$-30.96M-$-6.21M-$-5.66M
Free cash flow-$-175.95M-$-174.51M-$-12.73M$93.9M-$-87.44M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Immatics N.V.

        Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.

        CEO
        Harpreet Singh
        Employees
        678
        Beta
        1.32

        Explore

        Frequently asked questions

        What is the intrinsic value of Immatics N.V. (IMTX)?

        Immatics N.V. (IMTX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is IMTX undervalued?

        IMTX trades at a price of $5.77 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.